Johnny

#bitcoin, and Blockchain, Macro, secular trends, disruptive technologies

[Johnny @jokang623]

@DougKass I agree with your detailed analysis as CNBC being a rating grabbing TV show. I want to promote you to be the panelist for CNBC. Also, why do you work with Jim Cramer, who also is a marketer and in the same mold as Josh Brown and other CNBC panelists

[Bizagorana @bizagoranaa]

The power of a woman to man🔥
Look how she cooled down this bull 🐂

[Mario Nawfal @MarioNawfal]

This guy escaped the bull with a goated jump

[Johnny @jokang623]

@DougKass @JoeSquawk @POTUS @TheWhiteHouse @SquawkCNBC I have to agree. Joe Kernen needs to change

[Johnny @jokang623]

@BernieSanders Please do something. No more talks.

[Nicolas Hulscher, MPH @NicHulscher]

🚨BREAKING: Largest Real-World Study of Ivermectin + Mebendazole in Cancer Patients Shows 84.4% Clinical Benefit — Nearly HALF Report Cancer Disappearance or Tumor Regression

After just 6 months, 48.4% of cancer patients taking ivermectin and mebendazole reported NO EVIDENCE OF DISEASE (32.8%) or tumor regression (15.6%), while 36.1% reported disease stabilization⬇️

We have completed the largest real-world human analysis to date evaluating ivermectin and mebendazole in cancer patients—and the results represent one of the most compelling clinical signals ever documented for repurposed anti-parasitic therapies in oncology.

The groundbreaking analysis was made possible through a unique collaboration between The Wellness Company, the McCullough Foundation, and the Chairman of the President’s Cancer Panel (Dr. Harvey Risch)—uniting real-world clinical data, frontline medical experience, and high-level epidemiologic expertise to deliver urgently needed insights in oncology.

This was a real-world prospective clinical program evaluation of 197 cancer patients, with 122 completing a follow-up survey at about six months (61.9% response rate).

Cancer patients were prescribed compounded ivermectin–mebendazole, with each capsule containing 25 mg ivermectin and 250 mg mebendazole—most commonly taken at 1–2 capsules per day.

The cohort represented a clinically relevant population, including a wide variety cancer types, with 37.1% of patients reporting actively progressing disease at baseline and many having already undergone chemotherapy, radiation, and surgery.

At six months, 84.4% of cancer patients reported clinical benefit (Clinical Benefit Ratio: 84.4% [95% CI: 77.0–89.8%]):

✅ 32.8% reported no evidence of disease (95% CI: 25.1–41.5%)
✅ 15.6% reported tumor regression (95% CI: 10.2–23.0%)
✅ 36.1% reported stable disease (95% CI: 28.1–44.9%)

Treatment adherence was high, with 86.9% completing the full protocol and 66.4% remaining on therapy at six months.

The regimen was well tolerated, with 25.4% reporting side effects, primarily mild and gastrointestinal, and over 93% continuing treatment despite these events.

Patients were treated in real-world conditions alongside concurrent therapies, including chemotherapy (27.9%), radiation (21.3%), surgery (19.7%), supplements (49.2%), and dietary modification (37.7%), supporting use as an adjunctive approach.

Together, these findings represent a large, internally consistent real-world clinical signal that supports URGENT further investigation of ivermectin and mebendazole as low-toxicity, adjunctive cancer therapies.

Given the strength of the signal observed here, advancing this line of investigation is no longer optional—it is necessary.

This is NOT the end. We will continue advancing this work with larger datasets to further define and validate the role of anti-parasitics in cancer outcomes.

The manuscript is now available as a preprint on the Zenodo research repository, operated by the European Organization for Nuclear Research, while undergoing peer review at leading oncology journals: “Real-World Clinical Outcomes of Ivermectin and Mebendazole in Cancer Patients: Results from a Prospective Observational Cohort.”

@twc_health @McCulloughFund @P_McCulloughMD @DrHarveyRisch @DrKellyVictory @jathorpmfm @drdrew @PeterGillooly @FosterCoulson

[🎼🌺Music Love♥️ @ThoNg676733]

Absolutely unbelievable. The man is a legend.👏

[Johnny @jokang623]

@esidery @ShamsCharania Give more odds to play-in teams, so teams are incentivized to win rather than tanking. Teams with home court advantage should not receive any odds for the lottery

[Vala Afshar @ValaAfshar]

MIT professor delivers a brilliant masterclass on how to effectively present your ideas with clarity, high impact and purpose

[Tour Pro 🏌️‍♂️ @OfficialTourPro]

Sergio Garcia's lesson on how to properly start the downswing with the driver was really good.

[Save Gaza @Alee93ale]

🚨🇬🇧 BREAKING: British surgeon gives HORRIFYING testimony to the UK Parliament.

He describes how IDF drones arrive right after airstrikes in Gaza, targeting and shooting the injured, including children, right on the spot.

Repost this. Please I beg you

[Johnny @jokang623]

@tparsi No plan. 100%. The man is not able to strategize

[Trita Parsi @tparsi]

This is heartbreaking.

In play, children reenact what they see in order to make sense of it and feel a degree of control.

In Gaza, little girls play "funeral" with their doll playing the role of a friend who has been killed.

[Johnny @jokang623]

@shanaka86 @Selkis_2028 If I were iran, I would destroy helium plants and data plants. That will bring the war to end as Trump capitulates

[Johnny @jokang623]

@A_Ham96 I don’t understand why one person has so much power for so long. That is not good for a democratic country

[Alerta Mundial @TuiteroSismico]

ISRAEL AL BORDE DEL COLAPSO
Otro alcalde israelí dice: "Estamos destruidos... hemos estado viviendo en refugios durante semanas. Ya casi no dormimos!
¿Por qué somos nosotros los que estamos sufriendo ahora mismo? ¡Somos el pueblo elegido!"

[Johnny @jokang623]

@ProfessorPape When do you expect Houthi to participate? It seems they are vying for a right opportunity

[Dr Fab @Tufab]

How many women get mind like dis lady?